Aclaris Therapeutics (ACRS) Current Deferred Revenue (2024 - 2026)

Aclaris Therapeutics' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 2.16% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 2.16% YoY), while the FY2025 annual figure was $3.9 million, up 1.36% from the prior year.
• Current Deferred Revenue was $4.0 million for Q1 2026 at Aclaris Therapeutics, up from $3.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $25.8 million in Q2 2024 to a low of $3.8 million in Q3 2024.
• Historically, Current Deferred Revenue has averaged $6.6 million across 3 years, with a median of $3.9 million in 2025.
• Biggest YoY gain for Current Deferred Revenue was 4.25% in 2025; the steepest drop was 84.83% in 2025.
• A 3-year view of Current Deferred Revenue shows it stood at $3.9 million in 2024, then advanced by 1.36% to $3.9 million in 2025, then gained by 0.74% to $4.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $4.0 million (Q1 2026), $3.9 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.